Jinsong Yang, MD

Cancer Institute and Hospital Chinese Acedemy of Medical Sciences
Beijing, Beijing

Disclosure information not submitted.

Presentation(s):

• 3110 - Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial

  Tuesday, October 1, 2024
  12:45 PM – 2:00 PM ET